
At the beginning of 2025, Sten R. Sörensen announced Cereno Scientific’s positive Phase 2a results in PAH for lead asset CS1. He’s now moving forward with a global Phase 2b trial starting in Q2 2026. The company also progresses its second HDACi asset, CS014, toward Phase 2. Cereno's developing pioneering treatments with disease-modification potential for rare cardiovascular and pulmonary diseases.---Learn more about Cereno: https://bit.ly/cereno-e52---⭐️ ABOUT THE SPEAKERSten joined Cereno as CEO in 2015, with decades of experience in pharma, ranging from Monsanto Pharma to AstraZeneca.🔗 LINKS MENTIONEDCereno’s website - https://cerenoscientific.com/Cereno Scientific | BioStock Life Science Summit 2024 - [https://www.youtu.be/A5b3Ud_PSas](https://www.youtube.com/watch?v=A5b3Ud_PSas)Cereno Scientific announces positive topline results of Phase IIa trial with lead candidate CS1 in Pulmonary Arterial Hypertension **-** https://cerenoscientific.com/press-single/?releaseIdentifier=2D7F159764FDB891Cereno's HDAC inhibitor reduces risks from pulmonary arterial hypertension in phase 2 trial **-** https://www.fiercebiotech.com/biotech/cerenos-hdac-inhibitor-reduces-risks-pulmonary-arterial-hypertension-phase-2-trialCereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH) - https://cerenoscientific.com/press-single/?releaseIdentifier=008944355F62DA91Competing drug Winrevair / sotatercept by US Merck - https://www.drugs.com/winrevair.html📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/sten-sorensen-cereno-drug-repurposing/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:04] Cereno's Phase2A results[00:21:59] Phase2B[00:32:41] Cereno's pipeline[00:40:56] The finances of running a Phase2B[00:45:07] Investor base of Cereno[00:50:42] A strong team is crucial for Cereno[00:55:41] The Swedish biotech ecosystem[01:02:54] Sten Sörensen's background[01:10:39] Success in drug repurposing[01:16:03] Quickfire
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

CEO Jean-François Brepson on Scaling a CRO, and Selling to Charles River | E59 [Sponsored]

Ex-CEO of Incyte Hervé Hoppenot on 10x Growth, Biotech Cycles, and Breaking Bureaucracy | E58

Christoph Lengauer, Curie.Bio | Biotech Founders, Venture Capital | E57

Sander Slootweg, Forbion 🇳🇱 | European Biotech Investment, Venture Capital | E56
Free AI-powered recaps of Flot.bio x Philip Hemme and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.